학술논문
International, phase 3 trial: Balixafortide (a CXCR4 antagonist) plus eribulin versus eribulin alone in patients with HER2 negative, locally recurrent or metastatic breast cancer (FORTRESS) international, phase 3 trial: Balixafortide (a CXCR4 antagonist) plus eribulin versus eribulin alone in patients with HER2 negative, locally recurrent or metastatic breast cancer (FORTRESS)
Document Type
Journal
Author
Source
Subject
Language
English
ISSN
15387445